EGFR-IN-542 is a novel EGFR inhibitor. EGFR-IN-542 significantly reduces myocardial inflammation, fibrosis, apoptosis and dysfunction. It shows promise for use in the treatment of obesity-induced cardiac complications.
Mesdopetam (IRL790) is a dopamine D3 receptor antagonist with a Ki of 90 nM and an IC50 of 9.8 μM for the human recombinant D3 receptor. It exhibits psychomotor stabilizing properties and is utilized in the study of motor and psychiatric complications associated with Parkinson's disease.